Un estudio que compara Siplizumab con Globulina Anti-Timocítica de Conejo para ayudar al cuerpo a aceptar un trasplante de riñón (MODERNIZE1)
Estudio de Fase 2b, Aleatorizado, Multicéntrico, Doble Ciego, de Determinación de Dosis, Controlado Activamente de Siplizumab (TCD601) Comparado con Globulina Anti-Timocítica de Conejo en Receptores de Trasplante Renal que Requieren Terapia de Inducción y Reciben el Tratamiento Inmunosupresor Estándar con Tacrolimus, Ácido Micofenólico y Corticosteroides
The goal of this clinical trial is to learn if siplizumab can prevent rejection of a kidney transplant in adult participants with end stage kidney disease. The main questions it aims to answer are:
How many adverse events do participants receiving two different doses of siplizumab have compared to rabbit anti-thymocyte globulin (rATG)?
How many participants successfully keep their kidney transplant after receiving siplizumab or rATG? This will be calculated as those participants that did not: die; have their kidney fail to work properly (graft loss); their body rejects their transplant (tissue sample (biopsy)-proven acute rejection: BPAR); or who were lost to follow-up.
How does the body respond to siplizumab after dosing at each of the 2 dose levels?
How does siplizumab work in the body compared to rATG?
Selected participants will be divided into 3 groups. In 2 of the groups, participants will be given siplizumab at one of the two study medicine doses. Participants in the third group will be given rATG. All participants will take the usual anti-rejection medicines given before, during, and after a kidney transplant. All participants will also be given medicines before the study drug to lower the risk of reactions, and medicines used to prevent or treat infections after the transplant.
Participants will be asked to provide their medical history at the first visit at the study site where you will have your kidney transplant. At the first visit and other visits participants will be asked to provide their medication history, have a physical exam, check vital signs, have blood drawn for tests, and have non-invasive tests that record the electrical activity of your heart (ECG) and blood draws.
Participants will be monitored for 12 months after transplant surgery.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
Approximately 120 renal transplant candidates requiring induction therapy will be enrolled 1:1:1 to receive 1 of 2 dose levels of siplizumab or to the comparator rATG.
Randomization will be stratified by donor status (living vs donation after brain death vs donation after cardiac death) to ensure similar proportions of donor types in each study arm. All participants will also receive:
- A triple regimen (TAC, MPA, and CS) of background immunosuppressive therapy for the duration of the study.
- Premedication prior to study treatment infusions.
- Infection prophylaxis
This clinical trial will evaluate the safety of an anti-cluster of differentiation 2 (CD2) monoclonal antibody, siplizumab, compared to rATG as induction therapy in renal transplant recipients.
Following hospital discharge, participants will undergo assessments and procedures as indicated in the protocol through Month 12 or EOS, unless more frequent visits are required per local SoC or for laboratory specimen collection.
Safety assessments will include physical examinations, ECGs, vital signs, viral surveillance and monitoring, standard clinical laboratory evaluations completed centrally (hematology, clinical chemistry, urinalysis), and AE/SAE monitoring.
Final analysis will be performed when all participants have completed 12-month follow-up visits post-transplant or have otherwise ended the trial. This analysis will be performed to evaluate the safety of siplizumab at 2 dose levels compared to rATG.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brasil, 30150-320
- Reclutamiento
- Santa Casa Demisericordia de Belo Horizonte
-
Contacto:
- Pedro Macedo de Souza
- Número de teléfono: +55 (31) 3238-8975
- Correo electrónico: pmacedosouza@gmail.com
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasil, 90035-903
- Reclutamiento
- Hospital de Clinicas de Porto Alegre
-
Contacto:
- Research Coordinator
- Número de teléfono: +55 51 3359-6253
- Correo electrónico: l-genetica@hcpa.edu.br
-
Porto Alegre, Rio Grande do Sul, Brasil, 90020-090
- Reclutamiento
- Santa Casa de Misericordia de Porto Alegre - Hospital Dom Vincente Scherer
-
Contacto:
- Research Coordinator
- Número de teléfono: +55 51 3214-8640
- Correo electrónico: pesquisa@santacasa.org.br
-
-
São Paulo
-
São José do Rio Preto, São Paulo, Brasil, 15090-000
- Reclutamiento
- Fundação Faculdade Regional de Medicina de São José do Rio Preto - Centro Integrado de Pesquisa
-
Contacto:
- Research Coordinator
- Número de teléfono: +55 (17) 3201-5054
- Correo electrónico: osvaldo.junior@centrodepesquisacip.com.br
-
São Paulo, São Paulo, Brasil, 04038-002
- Reclutamiento
- Fundação Oswaldo Ramos - Hospital do Rim (HRIM)
-
Contacto:
- Research Coordinator
- Número de teléfono: +55 (11) 5087-8110
- Correo electrónico: hospital@hrim.com.br
-
-
-
-
-
Barcelona, España, 08035
- Reclutamiento
- Hospital Universitari Vall D'Hebron
-
Contacto:
- Study Coordinator
- Número de teléfono: +34 932746000
- Correo electrónico: assajos.nefrologia@vhir.org
-
Córdoba, España, 14004
- Reclutamiento
- Hospital Universitario Reina Sofía
-
Contacto:
- Álvaro Torres, MD
- Número de teléfono: +34 957010440
- Correo electrónico: nefro.hrs.sspa@juntadeandalucia.es
-
Málaga, España, 29010
- Reclutamiento
- Hospital Universitario Regional de Malaga
-
Contacto:
- Study Coordinator
- Número de teléfono: +34 951291174
- Correo electrónico: estudios.clinicos@ibima.eu
-
-
-
-
California
-
Los Angeles, California, Estados Unidos, 90033
- Reclutamiento
- Keck Hospital of the University of Southern California
-
Contacto:
- Melissa Ramos
- Número de teléfono: 323-442-7983
- Correo electrónico: Melissa.Ramos@med.usc.edu
-
Los Angeles, California, Estados Unidos, 90095
- Reclutamiento
- University of California - Los Angeles, Connie Frank Kidney Transplant Center
-
Contacto:
- Suphamai Bunnapradist, MD
- Número de teléfono: 310-794-8516
- Correo electrónico: bunnapradist@mednet.ucla.edu
-
Sacramento, California, Estados Unidos, 95817
- Reclutamiento
- UC Davis Medical Center
-
Contacto:
- Timothy Huynh, Clinical Research Coordinator
- Número de teléfono: 916-703-4471
- Correo electrónico: ttihuynh@health.ucdavis.edu
-
-
Florida
-
Tampa, Florida, Estados Unidos, 33606
- Reclutamiento
- Tampa General Hospital
-
Contacto:
- Jennifer Schmidt, BSN, RN
- Número de teléfono: 813-844-7041
- Correo electrónico: jenniferanilsen@tgh.org
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Reclutamiento
- Emory University Hospital
-
Contacto:
- Emily Temponi, Study Coordinator
- Número de teléfono: 404-712-1114
- Correo electrónico: emily.k.temponi@emory.edu
-
-
Kansas
-
Kansas City, Kansas, Estados Unidos, 66160
- Reclutamiento
- University of Kansas Hospital
-
Contacto:
- Adam Schooley, MA, CCRP
- Número de teléfono: 913-588-1699
- Correo electrónico: aschooley@kumc.edu
-
-
Kentucky
-
Lexington, Kentucky, Estados Unidos, 40536
- Reclutamiento
- University of Kentucky Healthcare
-
Contacto:
- Malay Shah, MD
- Número de teléfono: 859-338-1615
- Correo electrónico: malay.shah@uky.edu
-
-
Louisiana
-
Metairie, Louisiana, Estados Unidos, 70006
- Reclutamiento
- Tulane Medical Center
-
Contacto:
- Nicole Jackson
- Número de teléfono: 504-988-5344
- Correo electrónico: njackson3@tulane.edu
-
-
Massachusetts
-
Worcester, Massachusetts, Estados Unidos, 01655
- Reclutamiento
- UMass Chan Medical Center
-
Contacto:
- Anil Chandraker, MD
- Número de teléfono: 508-334-7087
- Correo electrónico: anil.chandraker4@umassmed.edu
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48109
- Reclutamiento
- University of Michigan - Michigan Medicine
-
Contacto:
- Nerissa Reister, Clinical Research Coordinator
- Número de teléfono: 734-763-5718
- Correo electrónico: naflow@med.umich.edu
-
Detroit, Michigan, Estados Unidos, 48202
- Reclutamiento
- Henry Ford Health
-
Contacto:
- Matthew Callaghan
- Número de teléfono: 313-916-4596
- Correo electrónico: mcallag2@hfhs.org
-
-
New Jersey
-
Livingston, New Jersey, Estados Unidos, 07039
- Reclutamiento
- Cooperman Barnabus Medical Center
-
Contacto:
- Jayrol Mock, APN
- Número de teléfono: 973-322-2339
- Correo electrónico: Jayrol.Mock2@rwjbh.org
-
-
New York
-
New York, New York, Estados Unidos, 10032
- Reclutamiento
- New York Presbyterian - Columbia University Irving Medical School
-
Investigador principal:
- Lloyd Ratner, MD
-
Contacto:
- Angela Sanchez, CRC
- Número de teléfono: 212-305-3839
- Correo electrónico: as5546@cumc.columbia.edu
-
Contacto:
- Theresa Lukose, Research Director
- Número de teléfono: 212-305-3839
- Correo electrónico: tt2103@cumc.columbia.edu
-
New York, New York, Estados Unidos, 10065
- Reclutamiento
- New York Presbyterian - Weill Cornell Medical Center
-
Contacto:
- Jennifer Lee
- Número de teléfono: 212-746-0192
- Correo electrónico: jel9109@nyp.org
-
Contacto:
- Meredith Aull
- Número de teléfono: 212-746-5330
- Correo electrónico: mea9008@med.cornell.edu
-
-
North Carolina
-
Durham, North Carolina, Estados Unidos, 27710
- Reclutamiento
- Duke University Medical Center
-
Contacto:
- Lynnette Moats
- Número de teléfono: 919-949-6574
- Correo electrónico: lynnette.moats@duke.edu
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75390
- Reclutamiento
- University of Texas Southwestern Medical Center
-
Contacto:
- David Wojciechowski, DO
- Número de teléfono: 214-645-7846
- Correo electrónico: David.Wojciechowski@UTSouthwestern.edu
-
-
Virginia
-
Falls Church, Virginia, Estados Unidos, 22042
- Reclutamiento
- Inova Fairfax Hospital
-
Contacto:
- Alma Khan, MSN, CCRC
- Número de teléfono: 703-776-5912
- Correo electrónico: Alma.Khan2@inova.org
-
Richmond, Virginia, Estados Unidos, 23298
- Reclutamiento
- Virginia Commonwealth University Health
-
Contacto:
- Meron Zeleke
- Número de teléfono: 804-628-4969
- Correo electrónico: Meron.Zeleke@vcuhealth.org
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98195
- Reclutamiento
- University of Washington Medical Center
-
Contacto:
- Belinda Pan, Research Coordinator
- Número de teléfono: 206-598-1562
- Correo electrónico: bcpan@uw.edu
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Recipients of a renal allograft from a non-HLA identical living or deceased donor.
- Recipients of a kidney with a cold ischemia time < 30 hours; hypothermic machine perfusion within the same timeframe is acceptable.
- Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, must agree to use highly effective methods of contraception.
Exclusion Criteria:
- Transplant recipients seronegative for EBV.
- Transplant recipients receiving a kidney from a non-heart beating donor (ie, DCD) whose organ is retrieved from an uncontrolled DCD or whose donor age > 55 years of age.
- Multi-organ transplant recipients (eg, kidney-pancreas, organ other than kidney), dual-kidney transplant recipients, recipients with more than one prior kidney transplant, or hematopoietic stem cell transplantation recipients.
- Presence of current or historical DSA via single-antigen bead assay or local SoC. The MFI cut-off value used to determine the presence of DSA will be defined as per the institutional SoC. Results within 3 months prior to transplant are acceptable.
- Crossmatch positive (isolated positive B cell crossmatches are not an exclusion criterion).
- ABO-incompatible recipient.
- Administration of complement inhibitor therapy within 6 months prior to the transplant, or likely to require treatment with complement inhibitor therapy during the study.
- Participants receiving immunosuppressive therapies prior to transplant for pre-existing conditions must be candidates for the protocol-defined regimen.
- History of malignancy of any organ system, except for localized excised non-melanomatous skin lesions or carcinoma in situ of the cervix.
- Seropositive for human immunodeficiency virus or hepatitis B surface antigen. Participants who are seropositive for hepatitis C virus (HCV) are excluded without proof of sustained viral response after anti-HCV treatment.
- Recipient of a kidney from a donor who tests positive for human immunodeficiency virus or hepatitis B surface antigen/hepatitis B core protein.
- History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes (eg, siplizumab, rATG, TAC, MPA derivatives, CS).
- Evidence of active tuberculosis (TB) infection (participants with a history of latent TB may become eligible after treatment with anti-TB therapy according to national guidelines).
- Participants with severe systemic infection(s), at the time of screening or within 2 weeks prior to randomization
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Siplizumab en dosis baja
|
A non-agonistic, humanized, anti-CD2 monoclonal antibody of the IgG1κ class
Otros nombres:
|
|
Experimental: Siplizumab en dosis alta
|
A non-agonistic, humanized, anti-CD2 monoclonal antibody of the IgG1κ class
Otros nombres:
|
|
Comparador activo: Globulina antitimocítica de conejo
|
An anti-human thymocyte immunoglobulin preparation made of purified polyclonal antibodies derived from rabbits
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Assessment of the safety of 2 dose levels of siplizumab versus rATG.
Periodo de tiempo: 12 months
|
Number and percentage of participants at 12 months post-transplant experiencing adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest (AESIs). |
12 months
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Periodo de tiempo: 12 months
|
|
12 months
|
|
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Periodo de tiempo: 12 months
|
• Grade of BPAR. |
12 months
|
|
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Periodo de tiempo: 12 months
|
• Severity of BPAR. |
12 months
|
|
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Periodo de tiempo: 12 months
|
|
12 months
|
|
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Periodo de tiempo: 12 months
|
|
12 months
|
|
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Periodo de tiempo: 12 months
|
• Number of participants requiring for-cause renal allograft biopsy assessments over 12 months post-transplant. |
12 months
|
|
Assessment of the pharmacokinetics (PK) of 2 dose levels of siplizumab.
Periodo de tiempo: 12 weeks
|
Siplizumab Cmax (maximum blood concentration) over 12 weeks post-transplant. |
12 weeks
|
|
Assessment of the pharmacokinetics (PK) of 2 dose levels of siplizumab.
Periodo de tiempo: 12 weeks
|
Siplizumab AUC (area under the concentration-time curve) over 12 weeks post-transplant. |
12 weeks
|
|
Assessment of the pharmacodynamics (PD) of 2 dose levels of siplizumab versus rATG.
Periodo de tiempo: 12 months
|
Depletion and recovery of lymphocyte count by subset (total lymphocytes; CD3+, CD4+, and CD8+ T cells; CD19+ B cells; CD56+ NK cells) over 12 months post-transplant. |
12 months
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- TCD601B205
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .